A Compassionate Access Protocol For Those Patients Who Have Completed A4001029
- Conditions
- HIV
- Registration Number
- NCT00801515
- Lead Sponsor
- ViiV Healthcare
- Brief Summary
This is a compassionate study to provide continued access to maraviroc for only those subjects completing study A4001029 who are showing clinical benefit. Assessments of safety and tolerability of maraviroc when added to OBT will be continued.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Patients having completed study A4001029 in Canada and still deriving clinical benefit.
Read More
Exclusion Criteria
- None
Read More
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇨🇦Montreal, Quebec, Canada